tepotinib,osimertinib
merck,astrazeneca
['insight-2', 'tepotinib', 'lcsm,(-blcsm)']
data from insight-2 presented by shows encouraging responses with osi + tepotinib. prior trials did not manage to present such impressive results. high response rates both for tissue or blood testing. less toxic than met abs such as ami? #asco23 #lcsm 
Husband, Father.
Medical Oncologist and Researcher focused in Thoracic Oncology.
Views are my own.